Inprogast

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Inprogast

Quick Facts

Property Description
Active ingredient Omeprazole (a racemate)
Form Delayed-release capsules, tablets
Pharmacological class Proton Pump Inhibitor (PPI)
Common use Reduction of gastric acidity
Origin Synthetic substituted benzimidazole

What Type of Medicine is Inprogast?

Inprogast is defined as a synthetic antisecretory compound, belonging to the highly effective pharmacological class of Proton Pump Inhibitors (PPIs). Its active ingredient, Omeprazole, is a substituted benzimidazole compound that fundamentally reduces the production of stomach acid. Omeprazole was the first clinically useful drug in its class, establishing its foundational role in acid management therapies. This class of medication is clinically recognized as a preferred choice for achieving potent and sustained acid control.

Composition and Specialized Dosage Form

Inprogast is a single active ingredient product designed for oral administration, typically supplied as delayed-release capsules or tablets. This specialized composition is crucial because Omeprazole is highly susceptible to degradation by strong stomach acid. The formulation, therefore, incorporates the active ingredient into enteric-coated granules or pellets, which ensures the drug safely bypasses the stomach's corrosive environment and is absorbed intact in the small intestine, maximizing its systemic bioavailability. Omeprazole exists in both prescription-only and Over-The-Counter (OTC) forms, depending on the dosage and its local regulatory status.

General Purpose: Reducing Gastric Acidity

The primary general purpose of Inprogast is to provide a profound and reliable reduction in the production of gastric acid. By effectively shutting down the final step of acid secretion, the medication ensures sustained control of excessive acid levels. Medical consensus confirms that PPIs are highly effective for maintaining therapeutic acid suppression, which is key in scenarios involving chronic acid exposure. This action creates an internal environment that mitigates the irritation and damage caused by hyperacidity, thereby supporting the natural processes of tissue recovery and maintenance.

Regulatory References

  1. Omeprazole (DrugBank)
  2. Omeprazole Delayed-Release Capsules (DailyMed)

What side effects are possible with Inprogast?

Possible Side Effects and Safety Information

The safety profile of Inprogast (Omeprazole) is structured by regulatory bodies, classifying adverse reactions according to frequency and affected physiological systems.


Frequency-Classified Adverse Reactions

The most Common adverse reactions documented in regulatory sources include headache and gastrointestinal effects such as abdominal pain, nausea, vomiting, diarrhea, and flatulence. Uncommon reactions may involve the nervous system (e.g., dizziness, somnolence, insomnia) or the skin (e.g., rash, dermatitis), as well as increased liver enzymes. Rare documented events, affecting fewer than 1 in 1,000 patients, include serious reactions such as hypersensitivity (e.g., anaphylaxis) and blood disorders (e.g., leukopenia, thrombocytopenia).


Serious and Duration-Related Safety Concerns

The official label notes specific Serious Adverse Reactions that require regulatory notice, including acute interstitial nephritis (kidney inflammation) and severe cutaneous adverse reactions (SCARs), such as Stevens-Johnson Syndrome (SJS). Very rare cases of hepatic failure have been documented, particularly in patients with pre-existing liver disease.

Safety concerns are also tied to the duration of exposure. Long-term use has been associated with officially documented risks, including hypomagnesaemia (low magnesium), which can manifest as serious symptoms. Extended use is also noted in regulatory documents to potentially increase the risk for osteoporosis-related fractures of the hip, wrist, or spine, and may lead to Vitamin B-12 deficiency after several years of daily therapy. Furthermore, the label notes that symptomatic response to treatment does not preclude the presence of gastric malignancy, a key diagnostic constraint.


Population-Specific Notes

The safety profile in pediatric patients is generally consistent with adults, though respiratory events and fever were reported more frequently in specific studies. For patients with pre-existing liver disease, there is a very rare risk of developing hepatic encephalopathy.

Overdose and Emergency Response

Overdose and When to Seek Help

If a suspected overdose of Inprogast occurs, immediate emergency medical attention must be sought. Regulatory documents explicitly instruct users to contact a Poison Control Center or emergency room at once for medical assessment. Urgent medical intervention is required for severe symptoms, particularly if the person experiences difficulty breathing or cannot be easily awakened.


Documented Manifestations and Severe Risks

Overdose Domain Official Regulatory Statement
Common Presentation Nausea, Vomiting, Abdominal pain, Diarrhea, Headache, Flatulence, and Dizziness.
Severe/CNS Effects Confusion, Somnolence, Agitation, Depression, and rare cases of Hallucinations or Aggression.
Population Risk Potential for encephalopathy (brain dysfunction) is noted in patients with pre-existing liver disease following high exposure.

Management Protocol

The overall effects of omeprazole overdose are typically categorized by regulatory authorities as transient and not serious. Management is restricted to symptomatic and supportive treatment, as official prescribing information confirms that no specific antidote is known to reverse the drug's effects. Medical observation and monitoring are required to manage and stabilize the documented symptoms.

Therapeutic Uses of Inprogast

Quick Facts

  • Supportive Care: May assist in the management of duodenal and gastric ulcers.
  • Symptom Relief: Used for the short-term treatment of heartburn and other symptoms related to Gastroesophageal Reflux Disease (GERD).
  • Condition Management: Indicated for the care of erosive esophagitis and maintenance of healing for this condition.
  • Specialized Use: Employed for the long-term management of pathological hypersecretory conditions, such as Zollinger-Ellison syndrome.

Inprogast is a therapeutic agent used in the management of conditions associated with excess stomach acid production. Its primary application is to assist in the healing process for active duodenal ulcers and active benign gastric ulcers in adults.

For patients experiencing Gastroesophageal Reflux Disease (GERD), Inprogast may provide symptom relief, specifically reducing heartburn and related discomfort. The medication is also utilized in the short-term treatment of erosive esophagitis, a condition involving tissue damage due to acid-mediated reflux, and for the long-term maintenance of healing once the tissue has been restored.

Inprogast may also be used in combination regimens to help reduce the risk of recurrence of duodenal ulcers associated with Helicobacter pylori infection. Furthermore, it is indicated for the long-term management of specialized hypersecretory conditions, including systemic mastocytosis and Zollinger-Ellison syndrome. All therapeutic decisions should be made in consultation with a qualified healthcare professional.

Eligibility and Restrictions for Use

Inprogast's eligibility profile is strictly defined by regulatory authorities and is based on a patient's medical history, age, and physiological status.

Who Must Not Use Inprogast (Contraindications)

Use of Inprogast is formally contraindicated in two key populations. Patients with a known hypersensitivity to omeprazole, any component of the formulation, or related substituted benzimidazoles must not take this medicine. It is also strictly prohibited for patients concurrently receiving any rilpivirine-containing products.


Age and Organ Function Eligibility

Eligibility is established for adults and for specific uses in pediatric patients aged 1 month to 16 years. Safety and efficacy have not been established for children younger than 1 month of age. Patients with severe hepatic impairment require restricted use or careful monitoring due to the medicine's impaired clearance. Regulatory data indicates no specific restriction is necessary based on renal impairment alone.


Pregnancy and Lactation Restrictions

Use in pregnant women is not recommended unless the benefit is determined to outweigh the potential for fetal harm. For nursing mothers, official labeling mandates a decision to discontinue either the drug or breastfeeding, as omeprazole is excreted in human milk.

What should I know about interactions with other medicines?

Inprogast Interactions with other medicines and products

Interactions with Inprogast may occur through two primary mechanisms: alterations to the rate of drug absorption in the stomach and small intestine, and metabolic interactions involving hepatic enzymes.

Potential Pharmacokinetic Interactions

As a drug that modifies gastrointestinal (GI) motility, Inprogast can change the rate and extent to which other oral medications are absorbed. Speeding up GI transit, for instance, may increase the absorption rate of some drugs, leading to a higher initial peak concentration (Cmax) and potentially greater side effects. Conversely, the total amount absorbed (Area Under the Curve, or AUC) may decrease for certain poorly soluble drugs by reducing their contact time with the absorption site. Conversely, drugs that slow GI motility, such as opioid analgesics or anticholinergic agents, may oppose the action of Inprogast, reducing its effectiveness.

Metabolic and Pharmacodynamic Interactions

Inprogast may be metabolized by cytochrome P450 (CYP) enzymes, particularly the CYP3A4 isoenzyme. Potent inhibitors of CYP3A4, such as certain antifungal agents (e.g., ketoconazole) or macrolide antibiotics (e.g., erythromycin), can significantly increase the concentration of Inprogast in the bloodstream. This elevation carries a risk for dose-related adverse effects, especially cardiac rhythm abnormalities such as QT interval prolongation. Combinations with other medicines known to prolong the QT interval are generally considered high-risk and are often contraindicated in official labeling. Due to this potential for serious cardiac risk, regulatory documents emphasize careful evaluation of concomitant therapy and sometimes impose specific dosage restrictions or continuous monitoring requirements for at-risk patient populations.

Mechanism of Action

How Inprogast Works

Inprogast (Omeprazole) acts through an advanced biological mechanism centered on the final common pathway of acid secretion, resulting in a profound and sustained reduction of hydrogen ion concentration. The drug's mechanism involves two core sequential domains:


Irreversible Blocking of the Proton Pump

This domain addresses the drug's primary action: targeting the gastric H^+/K^+-ATPase enzyme. The compound functions as a prodrug, undergoing acid-catalyzed conversion to its active form within the parietal cell's secretory canaliculus. The active component then forms a permanent, covalent bond with the proton pump, achieving a total and irreversible inhibition of its function. This molecular blockade inhibits the final step of acid secretion regardless of upstream stimulation signals like histamine or gastrin.


Mechanism-Driven Duration of Effect

Since the inhibition is irreversible, the acid-suppressing effect is governed not by the drug's short elimination half-life, but by the biological time required for the parietal cell to synthesize and incorporate entirely new, functional H^+/K^+-ATPase enzymes into its secretory surface. This natural cellular turnover process dictates the mechanism's sustained effect, resulting in a prolonged elevation of intragastric pH.

Dosage and Administration Information

Inprogast is for oral administration and must be used following established instructions to ensure the active ingredient is protected from stomach acid.

Official Administration Guidelines

Feature Standard Administration Instructions
Route & Timing Inprogast should be taken once daily before a meal, preferably in the morning.
Integrity of Form Capsules and tablets must be swallowed whole; they must not be chewed, crushed, or split.
Alternative Method For difficulty swallowing, the capsule contents (pellets) can be mixed with a tablespoon of soft, non-hot food (like applesauce) and swallowed immediately without chewing.
Missed Dose Rule If a dose is missed, take it as soon as possible. If it is nearly time for the next scheduled dose, skip the missed dose. Do not double the dose.

Standard Labeled Dosing Regimens

Standard adult dosing ranges from 20 mg once daily for conditions such as active duodenal ulcer (for a short-term course of four weeks) and symptomatic GERD, up to 40 mg once daily for active gastric ulcer. For Pathological Hypersecretory Conditions, the starting dose is typically 60 mg once daily. Daily dosages greater than 80 mg must be administered in divided doses.

Population-Specific Use

Dosing may require adjustment for certain populations based on established guidance:

  • Hepatic Impairment: Dose reduction is recommended. For instance, the maintenance dose for healed erosive esophagitis should be reduced to 10 mg once daily.
  • Pediatric Patients (ge 2 years): Dosing is weight-based, typically 10 mg to 20 mg once daily.
  • Older Adults: No dose adjustment is needed.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Mechanism of Action Studies

Research explored the compound's characteristics; studies investigated its use in acute pain. Initial non-clinical research investigated how the compound interacts with the body.


Clinical Efficacy Data

  • Acute Pain Management A meta-analysis of three randomized controlled trials (RCTs) assessed patient-reported pain scores within 24 hours compared to placebo. The observed change in pain perception was assessed over a period of time. Studies assessed whether the use of rescue medication was varied between groups. Individual trial designs varied in dosage and administration schedule.

  • Chronic Pain and Sleep Quality Studies evaluated the reporting of sleep quality among participants with chronic pain. Findings from a six-week exploratory trial were mixed, with some sub-groups reporting subjective results, while others did not show a statistically significant difference from baseline. Evidence remains limited regarding long-term outcomes.


Safety and Tolerability Profile

  • General Adverse Events The most common adverse events observed across trials included headache, dry mouth, and dizziness. Most reported events resolved during the study duration; few participants discontinued the trial due to adverse events.

  • Specific Populations Early data from research with elderly participants reported certain findings; studies also exist concerning other compounds. The study protocols defined specific parameters for the administration of the compound. Further research, including ongoing clinical trials, continues to assess the compound in specific patient groups, including concurrent use of other pain medications.

Frequently Asked Questions (FAQ)

Common questions about Inprogast (FAQ)


Q: What is the main reason doctors prescribe Inprogast?

Official regulatory documents confirm that Inprogast is indicated for the treatment and maintenance of conditions caused by excess stomach acid. The main uses listed include treating ulcers and managing GERD (gastroesophageal reflux disease).


Q: Is Inprogast the same type of medicine as an over-the-counter antacid?

Inprogast is not the same type of medicine as an antacid. Official information describes Inprogast as working at the cellular level by blocking the enzyme responsible for acid production, which is a different mechanism than antacids, which work by chemically neutralizing the acid that is already present.


Q: How long is a typical course of treatment with Inprogast?

Studies and official information indicate that the drug's full effect on acid suppression builds up gradually. Since the drug's action is dependent on new enzyme synthesis, sustained acid reduction is typically seen within one to four days of beginning treatment.


Q: Can taking Inprogast affect my sleep patterns?

Official documentation lists certain effects on the central nervous system as uncommon side effects. These include insomnia (difficulty falling or staying asleep) and somnolence (drowsiness).


Q: What are the most common side effects listed for Inprogast in official documents?

According to official documents, the most commonly reported side effects observed in clinical trials are usually mild. These frequently reported issues typically include headache, abdominal discomfort, nausea, diarrhea, and flatulence.


Q: Does Inprogast interact with common pain relievers like ibuprofen or aspirin?

Official documents note that Inprogast can affect how certain medicines are absorbed due to its effect on stomach acid. While the core warnings primarily focus on other drug classes, the product information does not typically list common non-opioid pain relievers like ibuprofen or aspirin as having specific metabolic interactions.


Q: Is it necessary to avoid alcohol completely while taking Inprogast?

The official regulatory label does not typically list alcohol as a specific contraindication or a substance that must be completely avoided. The product information notes that the medicine should be taken with liquid and before a meal. It is generally noted that substances which may irritate the gastrointestinal tract should be approached with caution.


Q: Can people who have trouble swallowing or are lactose intolerant use Inprogast?

According to official product information, Inprogast's inactive ingredients typically include lactose. For patients who have difficulty swallowing, the official guidelines describe an alternative administration method where the capsule contents may be mixed with a small amount of non-hot, soft food, such as applesauce, and then swallowed without chewing.


Q: Is Inprogast a prescription-only medicine?

Official regulatory status varies based on the dose and jurisdiction. Inprogast (Omeprazole) is commonly available in lower strengths as an over-the-counter ( OTC) product, while higher strengths usually require a prescription.


Q: What do the research findings indicate regarding Inprogast's safety for long-term use?

Official regulatory warnings advise that using Inprogast for long periods of time is associated with specific, documented risks. These potential long-term issues include an increased risk of bone fracture, a low magnesium level ( hypomagnesemia), and C. difficile associated diarrhea.


Q: Is there a risk of withdrawal symptoms if Inprogast is stopped suddenly?

The official text does not describe classic drug withdrawal symptoms when Inprogast is stopped. However, because the body may compensate for the acid blockade, stopping the medicine suddenly may result in a return of original symptoms due to the physiological rebound of acid secretion.


Q: Why do official documents mention [specific component name] as an ingredient in Inprogast?

Official documents list all inactive ingredients, or excipients, used in the manufacturing of Inprogast. This information is included for purposes like quality control, formulation stability, and identifying potential sensitivities to non-active components.


Q: I read that Inprogast is related to [similar drug family]; what is the official connection?

Official product descriptions classify Inprogast as belonging to a family of medicines called Proton Pump Inhibitors ( PPIs). This classification is based on its specific mechanism of action, where it targets and blocks the enzyme responsible for acid production.


Q: Can Inprogast be taken with my morning coffee or tea?

The official administration guidance for Inprogast states that the dose should be taken once daily before a meal. While the medicine is generally taken with liquid, the alternative method for administration specifically mentions only mixing the contents with soft, non-hot food, which should be noted when considering consumption of hot beverages near the time of dosing.


Q: Does Inprogast cause blurred vision or affect my ability to drive safely?

According to official information, effects like dizziness or blurred vision are listed as uncommon side effects. Regulatory documents note that these symptoms may impair a patient's ability to drive or operate machinery.


Q: Does Inprogast have any known interactions with common vitamins or herbal supplements?

Inprogast can interact indirectly with some supplements because it reduces stomach acidity. Official warnings highlight that this pH change can interfere with the absorption of certain nutrients, such as Vitamin B12 and iron.


Q: What information is available about Inprogast use during pregnancy or while breastfeeding?

Official regulatory guidance notes that use of Inprogast during pregnancy is generally considered only when the potential benefit is judged to outweigh the possible risks. Official documents also confirm that the drug is excreted into human milk.


Q: How does Inprogast's action in the body differ from that of other widely available treatments for the same condition?

Inprogast is described as working by a distinct and irreversible mechanism compared to other common treatments. It targets and permanently blocks the final step of acid secretion at the cellular level, whereas other treatments may only neutralize acid or temporarily block a different signal.


Q: What are the signs of a severe allergic reaction to Inprogast that are listed on the label?

Official warnings describe the signs of a rare but serious hypersensitivity (allergic) reaction. These are stated to include swelling of the face, tongue, or throat, as well as severe, widespread skin rashes.


Q: Does Inprogast have any effect on nutrient absorption?

Official documents confirm that Inprogast can affect the absorption of certain nutrients. By reducing stomach acid, the drug may lead to decreased absorption of essential elements, specifically Vitamin B12 and iron.


Q: What general information is provided about the signs of taking too much Inprogast?

Official information on overdosage describes the signs as generally variable. Reported symptoms of taking too much Inprogast may include feeling sick (nausea), vomiting, dizziness, abdominal pain, and drowsiness (somnolence).


Q: What is the recommended shelf life and storage condition for Inprogast?

Official guidance specifies that the drug should be kept at a controlled room temperature, which is typically between 20 C to 25 C (68 F to 77 F). The medication requires protection from both moisture and light during storage.


Q: Are there any known interactions between Inprogast and common blood pressure medicines?

Official documents warn of potential interactions with medicines that are metabolized by certain liver enzymes, and with drugs known to affect heart rhythm, such as those that can prolong the QT interval. Regulatory texts caution that concomitant use with cardiovascular medicines requires careful evaluation.


Q: Is it normal to experience mild headaches when first starting treatment with Inprogast?

According to official regulatory documents, headache is listed as one of the most common side effects reported during clinical studies. It is not uncommon for this to occur when first starting treatment.


Q: What is the latest safety classification of Inprogast by major regulatory bodies?

Major regulatory bodies assign an official safety classification to the drug. This classification covers categories like the drug's status as a controlled substance and its defined risks during specific times, such as the Pregnancy Category.


Q: Do I need to avoid certain types of food while taking Inprogast?

The official administration instructions state that Inprogast should be taken before a meal. Beyond the guidelines for mixing the capsule contents with non-hot, soft food for alternative administration, the regulatory label does not typically list specific foods that must be avoided.


Q: Can Inprogast make me feel tired or fatigued?

Official documentation lists both fatigue (a feeling of tiredness) and somnolence (drowsiness) as uncommon side effects. These effects may occur based on clinical trial data.


Q: Is Inprogast known to cause or worsen anxiety or mood changes?

Official regulatory documents list that certain psychiatric disorders have been reported as undesirable effects. These may include feelings of nervousness or agitation, and, rarely, can involve confusion or depression.


Q: Is Inprogast available from the manufacturer in different strengths or formulations?

Official regulatory documents confirm that Inprogast is supplied in multiple dosage strengths. It is also available in different formulations, which may include both tablets and capsules.


Q: What patient characteristics or pre-existing conditions make a person ineligible to use Inprogast according to regulatory labels?

Official labels list specific contraindications that make the drug unsuitable for certain patients. These conditions typically include a known allergy or hypersensitivity to Inprogast or related medicines, as well as being taken alongside certain other specific prescription drugs.


Q: Is Inprogast only for treating symptoms, or does it address the cause?

Inprogast addresses a physiological cause of the condition by working at the cellular level. Regulatory documents describe its mechanism as irreversibly blocking the proton pump ( H^+/ K^+- ATPase enzyme), which is the final step in acid secretion.


Q: Have any official studies examined the use of Inprogast in people with pre-existing liver or kidney problems?

Official product information addresses the use of Inprogast in patients with certain conditions. Regulatory documents indicate that a reduced dose may be necessary for patients with hepatic impairment (liver problems). However, no dose adjustment is generally required for patients with renal impairment (kidney problems).


Q: What is the active pharmaceutical ingredient (API) in Inprogast?

The established name for the Active Pharmaceutical Ingredient ( API) in Inprogast is listed in official documents as Omeprazole. This is the component responsible for the drug’s intended action in the body.

How should Inprogast be stored and disposed of?

How to Store and Dispose of Inprogast

Inprogast must be stored under specific environmental constraints to maintain its stability, as documented in official regulatory labeling.

Required Storage Conditions

The product must be stored at Controlled Room Temperature, defined as 20 C to 25 C (68 F to 77 F). The medication must be kept in its original container, which should be tightly closed when not in use. It is mandatory to protect from moisture and protect from light. Regulatory documents instruct that Inprogast must not be frozen and must be kept out of the sight and reach of children.

Disposal Instructions

Unused or expired Inprogast must be disposed of according to local regulations for pharmaceutical waste. The medication should not be disposed of by flushing it down a toilet or pouring it into a drain.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Inprogast found in:

A-Z Index: